Core--Tissue procurement

描述：(申请人描述)这个核心的目的是为整个孢子提供资源，并为目前和未来的项目和先导研究提供宝贵的生物材料来源。实验室核心将负责收集、储存和分发卵巢组织和肿瘤。新鲜/冷冻的样本将在联合国气候变化框架公约和其他参与地点收集，并转发到我们的核心实验室。这一实验室核心还将负责收集卵巢肿瘤档案标本和提取DNA，分发给参与的项目和先导研究。据估计，在我们的建议过程中，每年通过OCCN(见核心1)发现的卵巢癌新病例将超过400例。据非常保守的估计，这些病例中约有30%将作为新鲜/冷冻标本积累。石蜡包埋肿瘤将从所有病例中获得。项目1、2、3和5将使用肿瘤样本。此外，我们将从参与我们的化学预防试验(见项目4)的被认为患卵巢癌风险较高的女性(例如BRCA1、BRCA1突变等位基因携带者或有癌症家族史的女性)中收集卵巢切除用于预防。这些组织将被加工和分配以进行病理学和免疫组织化学评估，以确定芬维甲素和其他化学预防药物对我们之前在高危卵巢中观察到的易患癌症表型的影响。通过将这些服务集中到一个核心中，我们将能够更好地管理和协调大量高价值的肿瘤、癌症易患和正常标本的收集、存储和分发。

DESCRIPTION: (Applicant's Description) This core is intended to be a resource for the SPORE as a whole and a valuable source of biological materials for the present and future projects and pilot studies. The laboratory core will be responsible for the collection, storage, and distribution of ovarian tissues and tumors. Fresh/frozen samples will be collected at FCCC and other participating sites and forwarded to our core laboratory. This laboratory core will also be responsible for the collection of archival ovarian tumor specimens and the extraction of DNA to be distributed to the participating projects and pilot studies. It is estimated that more than 400 new ovarian cancers cases will be identified each year through the OCCN (see Core 1) during the course of our proposal. It is very conservatively estimated that approximately 30 percent of these cases will be accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor samples will be used by Projects 1, 2, 3 and 5. In addition, we will collect ovaries removed for prophylaxis from women considered to be at increased risk of developing ovarian cancer (e.g., BRCA1, BRCA1 mutant allele carriers, or suggestive family history of cancer) who participate in our chemoprevention trial (see Project 4). These tissues will be processed and distributed for pathology and immunohistochemical evaluation to determine the effect of fenretinide and other chemopreventive agents on the cancer-prone phenotype that we have previously observed in at risk ovaries. By centralizing these services into a core, we will be better able to manage and coordinate the collection, storage, and distribution of a large number of highly valuable tumor, cancer-prone and normal specimens.